Colorectal Cancer

The FDA has waived the need for a botensilimab monotherapy arm in the phase 3 BATTMAN trial evaluating the combination in MSS metastatic colorectal cancer.

Subgroup data from BREAKWATER support cetuximab/encorafenib plus mFOLFOX6 as a new standard of care in BRAF V600E-mutated metastatic colorectal cancer.

Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

Data from part B of the DeFianCe study demonstrate a positive overall response rate trend with sirexatamab plus bevacizumab and chemotherapy.

Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

Aspirin led to a median disease-free survival of 1.16 years vs 1.35 years with placebo in patients with colorectal cancer liver metastases.

A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.

As a single agent or in combination, MK-1084 showed promising efficacy and safety results for patients with KRAS G12C–mutated CRC.

Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.

The median PFS was 54.1 months with nivolumab/ipilimumab vs 5.9 months with chemotherapy in patients with MSI-H/dMMR CRC.

Anlotinib/chemotherapy showed comparable efficacy vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.

Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.

Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.

For patients with right-sided CRC tumors, no significant progression-free survival difference was observed between the cetuximab and FOLFIRI-only groups.

At the time of analysis, the median progression-free survival was not reached with fruquintinib plus capecitabine in a phase 1/2 trial.

Patients with MSS tumors diagnosed with metastatic CRC did not experience enhanced OS outcomes with frontline ICI therapy compared with chemotherapy.

Results from the phase 3 CodeBreaK trial support the use of 960 mg of sotorasib plus panitumumab as standard of care in metastatic colorectal cancer.

Treatment-related adverse events of special interest occurred in 64.9% of patients who received fruquintinib and 23.0% of those who received placebo.

Although the overall incidence of colorectal adenocarcinoma is decreasing, the reduction is primarily associated with patients 55 years or older.

A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.

Muhammad Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

Laparoscopic, histologic, and biomarker responses occurred at all dose levels of mitomycin treatment in patients with peritoneal metastases.

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Antitumor efficacy end points favored placebo over trilaciclib prior to FOLFOXIRI/bevacizumab in patients with untreated metastatic colorectal cancer.

In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.

Efficacy results demonstrated by regorafenib and sintilimab in patients with mSS mCRC were dependent on patient characteristics such location of metastasis and RAS type.